Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 12/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.74 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CD74 | P04233 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14328165 | 0.88 | HDAC8 (0.79) | HDAC8HDAC6NOTUML3MBTL1 | |
| SCHEMBL14324511 | 0.87 | HDAC8 (0.77) | HDAC8HDAC6NOTUML3MBTL1DRD2 | |
| SCHEMBL14328280 | 0.85 | HDAC8 (1.00) | HDAC8HDAC6NOTUMDRD2DRD4 | |
| SCHEMBL14323424 | 0.85 | HDAC8 (0.73) | HDAC8HDAC6NOTUML3MBTL1DRD2 | |
| SCHEMBL14323561 | 0.84 | HDAC8 (0.72) | HDAC8HDAC6NOTUML3MBTL1DRD2 | |
| SCHEMBL14322781 | 0.84 | HDAC8 (0.72) | HDAC8HDAC6NOTUML3MBTL1DRD2 | |
| SCHEMBL14323931 | 0.83 | HDAC8 (0.70) | HDAC8HDAC6NOTUML3MBTL1DRD2 | |
| SCHEMBL14322583 | 0.81 | HDAC8 (0.67) | HDAC8HDAC6NOTUML3MBTL1DRD2 | |
| SCHEMBL14323393 | 0.74 | HDAC8 (0.58) | HDAC8HDAC6NOTUML3MBTL1DRD2 | |
| SCHEMBL14328164 | 0.74 | HDAC8 (0.60) | HDAC8HDAC6NOTUML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | HDAC5, HDAC3, HDAC1 | HDAC8 9/4885HDAC6 11/4885NOTUM 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.